|Euro Pacific Canada||Douglas Loe|
|Leerink Swann||Howard Liang|
|Stifel Nicolaus||Stephen Willey|
|William Blair||Katherine Xu|
OncoGenex Pharmaceuticals, Inc. is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding OncoGenex Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of OncoGenex Pharmaceuticals, Inc. or its management. OncoGenex Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2017 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.